Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

FRI0021 Alx-0061, an anti-IL-6r nanobody® for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab

(2014) M. Van Roy et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0117 Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Inhibitor of The IL-6 Receptor: Relationship Between Eular Responses and Change from Baseline of Selected Clinical Parameters

(2014) M. C. Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA

(2014) J.-B. Holz et al.   ANNALS OF THE RHEUMATIC DISEASES

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) B. Hsu et al.   ANNALS OF THE RHEUMATIC DISEASES

AB0037 Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha

(2014) A. Rafique et al.   ANNALS OF THE RHEUMATIC DISEASES

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

(2014) B. Hsu et al.   ANNALS OF THE RHEUMATIC DISEASES

FRI0181 Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active ra despite methotrexate therapy: Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study

(2014) B. Hsu et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

(2014) Cécile Gaujoux-Viala et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 Regulates Neutrophil Trafficking during Acute Inflammation via STAT3

(2014) C. A. Fielding et al.   JOURNAL OF IMMUNOLOGY

Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis

(2014) M. A. Nowell et al.   JOURNAL OF IMMUNOLOGY

Interleukin 6 and Rheumatoid Arthritis

(2014) Yuji Yoshida et al.   Biomed Research International

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects

(2013) Yanli Zhuang et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38

(2013) Gaëlle Clavel et al.   JOINT BONE SPINE

Do we need therapeutic trials comparing biotherapies to guide treatment selection in patients with rheumatoid arthritis?

(2013) Maxime Dougados   JOINT BONE SPINE

Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

(2013) Cem Gabay et al.   LANCET

The problem of choice: current biologic agents and future prospects in RA

(2013) Ernest H. Choy et al.   Nature Reviews Rheumatology

Cord Blood-Derived Macrophage-Lineage Cells Rapidly Stimulate Osteoblastic Maturation in Mesenchymal Stem Cells in a Glycoprotein-130 Dependent Manner

(2013) Tania J. Fernandes et al.   PLoS One

Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis

(2013) A. Thiolat et al.   Arthritis & Rheumatology

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

(2012) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

(2012) Maxime Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

(2012) Maxime Samson et al.   ARTHRITIS AND RHEUMATISM

The role of tocilizumab in the management of rheumatoid arthritis

(2012) Zoe Ash et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

Rheumatoid arthritis: From autoimmunity to synovitis and joint destruction

(2012) Marie-Christophe Boissier et al.   JOURNAL OF AUTOIMMUNITY

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

(2011) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study

(2011) Zhenhua Xu et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The regulation of TNF signalling: what a tangled web we weave

(2011) John Silke   CURRENT OPINION IN IMMUNOLOGY

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Whole-Molecule Antibody Engineering: Generation of a High-Affinity Anti-IL-6 Antibody with Extended Pharmacokinetics

(2011) Donna K. Finch et al.   JOURNAL OF MOLECULAR BIOLOGY

When should we use rituximab to treat RA?

(2011) Yusuf Yazici   Nature Reviews Rheumatology

Treating rheumatoid arthritis to target: recommendations of an international task force

(2010) J. S. Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

IL-6: from its discovery to clinical applications

(2010) T. Kishimoto   INTERNATIONAL IMMUNOLOGY

Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis

(2010) Nicolas Frey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer

(2009) Sergei Grivennikov et al.   CANCER CELL

Targeting lymphocyte activation to treat rheumatoid arthritis

(2009) Géraldine Falgarone et al.   JOINT BONE SPINE

Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration

(2009) Claudia Drucker et al.   JOURNAL OF AUTOIMMUNITY

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

(2009) Peter C. Taylor et al.   Nature Reviews Rheumatology

Interleukin-17 and Type 17 Helper T Cells

(2009) Pierre Miossec et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

(2008) N. Nishimoto et al.   BLOOD

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET